Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00074867
Status:
COMPLETED
Last Update Posted:
2006-11-07
First Post:
2003-12-22
Brief Title:
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian Peritoneal Fallopian Tube Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer Primary Peritoneal Serous Cancer Or Fallopian Tube Cancer
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether CP-547632 an oral VEGFR-2 tyrosine kinase inhibitor is effective in the treatment of epithelial ovarian cancer primary peritoneal serous cancer or fallopian tube cancer for patients who have failed first line platinum-based therapy and have a persistent rising CA-125
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None